Back
Trimboli_2022_Spri_endocrine_3
Journal article

The performance of levothyroxine tablet is impaired by bariatric surgery

  • Trimboli, Pierpaolo ORCID Servizio di Endocrinologia e Diabetologia, Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland - Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland
  • Ossola, Nicola Servizio di Nutrizione Clinica e Dietetica, Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland
  • Torre, Alessandro ORCID Servizio di Chirurgia, Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland
  • Mongelli, Francesco Servizio di Chirurgia, Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland
  • Quarenghi, Massimo ORCID Servizio di Nutrizione Clinica e Dietetica, Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland
  • Camponovo, Chiara Servizio di Endocrinologia e Diabetologia, Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland - Servizio di Nutrizione Clinica e Dietetica, Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland
  • Lucchini, Barbara Servizio di Endocrinologia e Diabetologia, Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland - Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland
  • Rotondi, Mario ORCID Unit of Internal Medicine and Endocrinology, Laboratory for Endocrine Disruptors, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy - Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
  • Ruinelli, Lorenzo Team Data Science & Research, Area ICT, Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland - Clinical Trial Unit, Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland
  • Garofalo, Fabio Servizio di Chirurgia, Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland
Show more…
  • 2022
Published in:
  • Endocrine . - 2022
Hypothyroidism
Bariatric surgery
Levothyroxine
Tablet
Formulations
English Objective: The aim was to evaluate if bariatric surgery can affect the LT4 performance. The endpoints were the following: 1) difference between LT4 daily dose before and 1 year after surgery, 2) difference between LT4 dose per weight before and 1 year after surgery, 3) difference among LT4 preparations. Methods: The study period was between January 2018 and May 2022. Inclusion criteria were a) adults undergone bariatric surgery, b) with proven autoimmune hypothyroidism, c) on LT4 therapy before bariatric surgery, d) using any commercialized LT4 preparation. Excluded were patients a) proven to have or suspected for pre-surgical intestinal malabsorption, b) with other potential interfering factors on LT4 absorption; c) with heart, renal, and/or hepatic failure, d) with recent/current infection/inflammation, e) in pregnancy, f) with incomplete data about LT4 therapy. Results: According to the selection criteria, 40 patients were included. Both TSH and LT4 daily doses were not significantly different with respect to baseline values. On the contrary, the LT4 dose per weight was significantly increased, especially in RYGB patients. An increased LT4 dose per weight was observed with the reduction of weight. Conclusion: One year after bariatric surgery 1) the daily dose of LT4 remains unchanged, and 2) despite the significant weight reduction, LT4 dose per weight increases. Most data are referred to LT4 tablet and the performance of LT4 caps should be further investigated.
Collections
Language
  • English
Classification
Medicine
License
CC BY
Open access status
hybrid
Identifiers
Persistent URL
https://n2t.net/ark:/12658/srd1324942
Statistics
Document views: 12 File downloads:
  • Trimboli_2022_Spri_endocrine_3.pdf: 29